Women's International Pharmacy

What Women's International Pharmacy does

Women's International Pharmacy, founded in 2013 and rebranded to Belmar Pharmacy in July 2024, is a national compounding pharmacy operating as a wholly-owned subsidiary of Belmar Midco, Inc. The company specializes in personalized medicine with a core focus on bioidentical hormone replacement therapy (BHRT), complemented by sterile injectables, thyroid medications, hormone pellets, weight management formulations, and sexual health products for both women and men.

The technical core is a 503A compounding pharmacy model augmented by 503B outsourcing facility registration, with production sites spanning Colorado (headquarters and Lakewood 503B facility), Arizona, Florida, Kansas, and Wisconsin. This dual 503A/503B posture permits both patient-specific prescriptions and office-use clinician fulfillment, supporting national distribution. NAPB accreditation and Alliance for Pharmacy Compounding membership serve as external quality validations. Educational content on hormone health, menopause, thyroid function, and related topics functions as a content-marketing engine for organic patient and prescriber acquisition.

The business model is prescription-driven: revenue is generated per compounded medication dispensed, with pay-as-you-go pricing that varies by formulation, dosage, and insurance coverage. The go-to-market motion combines direct-to-consumer patient services (refills, pharmacist consultations, new prescriptions) with a prescriber channel (clinician accounts, office-use orders). The customer base spans individual patients seeking BHRT and related therapies and healthcare practitioners, with telemedicine provider integration extending digital access. Recurring refill behavior produces a subscription-like revenue cadence despite per-prescription billing.

Name

Women's International Pharmacy

Legal name

Women's International Pharmacy

Website

https://womensinternational.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

101–250 employees

Short description

Women's International Pharmacy (now Belmar Pharmacy) is a national 503A/503B compounding pharmacy subsidiary of Belmar Midco, Inc., specializing in bioidentical hormone replacement therapy, sterile injectables, and personalized medications for individual patients and healthcare practitioners across the United States.

Ownership category

akta.pro rank

Product category

Compounding Pharmacy Services

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmacies and Drug Retailers (45611)

SIC

Pharmaceutical Preparations (2834), Retail-Drug Stores And Proprietary Stores (5912)

akta.pro primary industry

Specialty Pharmacies (Complex/High-Cost Therapies) (HLAFALAC)

akta.pro secondary industries

Women’s Health & Reproductive Specialty Pharmaceuticals (HLAIACAN), Central Fill & Pharmacy Outsourcing Services (HLAFALAM)

Keywords

• Compounding pharmacy services
• Bioidentical hormone therapy
• Hormone replacement medications
• Sterile injectable medications
• Custom compounded prescriptions

Headquarters

HQ city

Madison

HQ country

United States

HQ region

North America

Offices7 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Supply Chain, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Prescription Compounded Medications: Revenue generated from compounding customized medications, primarily bioidentical hormones, sterile injectables, and specialty formulations prescribed by healthcare providers. Services include prescription dispensing, refills, and pharmacist consultations.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Women's International Pharmacy (now operating as Belmar Pharmacy) is a national compounding pharmacy that prepares custom prescription medications, with a core focus on bioidentical hormone replacement therapy (BHRT), sterile injectables, hormone pellets, and thyroid formulations. The pharmacy operates as a 503A compounding pharmacy and a 503B outsourcing facility, dispensing personalized medications to patients and healthcare practitioners nationwide.

Product overview

Women's International (now Belmar Pharmacy) is a national 503A compounding pharmacy and 503B outsourcing facility specializing in personalized medicine through compounded medications and bioidentical hormone replacement therapy (BHRT). The product portfolio includes core offerings of compounded medications and BHRT, supplemented by specific therapeutic categories including thyroid medications, hormone pellets, weight management products, sterile injectables, and sexual health products for both women and men. The company also provides extensive educational resources on hormone health and wellness topics. The rebranding to Belmar Pharmacy consolidated operations while maintaining the same prescriptions, compounding pharmacists, and exceptional service.

Differentiator

Problem solved

Functional benefit

Products and services

• Compounded Medications Custom-compounded prescription medications prepared by licensed pharmacists to meet individual patient needs.
• Bioidentical Hormone Replacement Therapy (BHRT) Compounded bioidentical hormones designed to address hormone imbalances in women and men, including menopause, andropause, thyroid disorders, and other hormonal conditions.
• Sterile Injectables

Quantifiable outcome

• National compounding pharmacy serving patients and healthcare providers across the United States
• +1 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered minor.

• LDN Research TrustminorOthersPartnership with LDN Research Trust, an organization focused on Low Dose Naltrexone research, indicating collaboration in specialized therapeutic areas.
• Telemedicine ProvidersminorStrategic or Co-development PartnerSupport for telemedicine services, enabling healthcare providers to consult with patients remotely and facilitate prescription services through digital health platforms.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Hallandale Pharmacy: Florida-based compounding pharmacy offering bioidentical hormone pellets and BHRT products through a presсriber network. Comparable women's and men's hormone therapy offerings with overlapping practitioner channel.
• Innovation Compounding: Specialty compounding pharmacy offering BHRT, thyroid, sexual health, and sterile injectable preparations through a prescriber and patient channel. Closely comparable product mix and clinical positioning.
• VLS Pharmacy: 503A compounding pharmacy specializing in bioidentical hormone replacement therapy, sterile injectables, and men's and women's health formulations. Direct BHRT competitor serving a similar prescriber-driven patient base.
• Koshland Pharm: California-based compounding pharmacy with a strong focus on bioidentical hormone replacement and personalized prescriptions. Comparable niche specialization in women's hormone health and direct-to-patient dispensing model.
• AnazaoHealth: National 503A/503B compounding pharmacy headquartered in Florida with additional 503B outsourcing capacity, providing compounded sterile preparations and hormone therapies. Comparable multi-state compounding infrastructure and prescriber-channel GTM.
• ImprimisRx: Specialty compounding pharmacy offering customized hormone, ophthalmic, and pain medications to prescribers and patients nationally. Overlaps directly in hormone replacement therapy formulations and prescriber-channel distribution.
• Empower Pharmacy: Largest 503A/503B compounding pharmacy in the U.S., offering a broad portfolio of compounded hormones, sterile injectables, and specialty medications to patients and prescribers nationally. Direct competitor with overlapping BHRT, thyroid, and men's/women's sexual health product lines.

Broad incumbents

• Fagron Sterile Services: U.S. arm of global compounding leader Fagron, operating 503B outsourcing capacity for sterile preparations and bulk APIs. Larger, broader portfolio competitor in the 503B outsourcing segment serving hospital and clinic customers.

Emerging players

• TheraComp RX: Emerging national compounding pharmacy with BHRT and men's/women's health focus, marketing heavily to functional medicine and integrative prescribers. Emerging threat in the same hormone-therapy niche.

Others

• PCCA (Professional Compounding Centers of America): Industry supplier and education provider for compounding pharmacists, distributing APIs, bases, and training to thousands of independent compounders. Comparable market context as the ecosystem in which Women's International operates, though not a direct dispensing competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights5 records

Customer concentration

• Facebookfacebook.com/womensinternational
• LinkedInlinkedin.com/company/1593899

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Women's International Pharmacy